Search Within

Jedd D Wolchok

  1. "Elsevier Science, Inc."
Formats
  1. Journal Article (17)
  2. Meeting Abstract (11)
Groups
  1. Department of Medicine (28)
  2. GSK Faculty (28)
  3. Melanoma and Immunotherapeutics Service (28)
  4. Solid Tumor Oncology Division (28)
  5. Dermatology (10)
  6. Dermatology Service (10)

More Groups

People
  1. Taha Merghoub (8)
  2. Liang Deng (7)
  3. Allan Halpern (5)
  4. Stewart Shuman (5)
  5. Alan Houghton (4)
  6. Ning Yang (4)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (2)
  6. 2017 (3)

More Years

Publications
  1. Journal of Investigative Dermatology (14)
  2. Lancet Oncology (11)
  3. Lancet (1)
  4. Ophthalmology (1)
  5. Urology (1)
Publishers
  1. Elsevier Science, Inc. (28)

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reprogramming the tumor microenvironment by a second-generation recombinant modified vaccinia virus Ankara
    Meeting Abstract

    Liu, S.; Mazo, G.; Yang, N.; Zhang, T.; Tariq, S. B.; Wang, Y.; Hirschhorn-Cymerman, D.; Ji, L.; Tan, A.; Wang, J.; more...
    Journal of Investigative Dermatology (2022)

    Fulltext@MSK | Save
  • Rational engineering of recombinant modified vaccinia virus Ankara to enhance both innate and adaptive immunity for cancer immunotherapy
    Meeting Abstract

    Yang, N.; Wang, Y.; Liu, S.; Luna, J.; Rossi, A.; Mazo, G.; Tan, A.; Wang, J.; Yan, W.; Choi, J.; more...
    Journal of Investigative Dermatology (2021)

    Fulltext@MSK | Save
  • Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition: Unmasking and masquerading
    Journal Article

    Francis, J. H.; Berry, D.; Abramson, D. H.; Barker, C. A.; Bergstrom, C.; Demirci, H.; Engelbert, M.; Grossniklaus, H.; Hubbard, B.; Iacob, C. E.; more...
    Ophthalmology (2020)

    Fulltext@MSK | Save
  • Rational design of recombinant modified vaccinia virus Ankara for cancer immunotherapy
    Meeting Abstract

    Yang, N.; Wang, Y.; Shuman, S.; Merghoub, T.; Wolchok, J. D.; Deng, L.
    Journal of Investigative Dermatology (2019)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    Journal Article

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • The combination of intratumoral delivery of inactivated modified vaccinia virus Ankara with systemic delivery of immune checkpoint blockade enhances antitumor immunity
    Meeting Abstract

    Wang, W.; Dai, P.; Yang, N.; Wang, Y.; Shuman, S.; Merghoub, T.; Wolchok, J.; Deng, L.
    Journal of Investigative Dermatology (2018)

    Fulltext@MSK | Save
  • Future cancer research priorities in the USA: A Lancet Oncology Commission
    Journal Article

    Jaffee, E. M.; Dang, C. V.; Agus, D. B.; Alexander, B. M.; Anderson, K. C.; Ashworth, A.; Barker, A. D.; Bastani, R.; Bhatia, S.; Bluestone, J. A.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): Secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
    Journal Article

    Coens, C.; Suciu, S.; Chiarion-Sileni, V.; Grob, J. J.; Dummer, R.; Wolchok, J. D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P. A.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics
    Journal Article

    Seymour, L.; Bogaerts, J.; Perrone, A.; Ford, R.; Schwartz, L. H.; Mandrekar, S.; Lin, N. U.; Litiè€re, S.; Dancey, J.; Chen, A.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
    Journal Article

    Hodi, F. S.; Chesney, J.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; Agarwala, S. S.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save